Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06511674
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-04
Brief Title:
Vulnerability and Risk of Neuropathic Pain in Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Vulnerability and Risk of Neuropathic Pain in Cancer Validation of a Predictive Tool to Optimize Treatment
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CANOPY
Brief Summary:
Successive and repeated therapeutic interventions during cancer management - surgery chemotherapy radiotherapy - can all to varying degrees generate acute pain central pain sensitization and chronic pain Almost 58 of patients suffer from chronic pain often of the neuropathic type with altered quality of life and disease burden amplified by difficulty in achieving effective relief
Indeed neuropathic pain in cancer remains difficult to treat often arrives insidiously may persist well beyond cancer remission and frequently has a fate that is difficult to predict Current treatments for neuropathic pain are based on the recommendations of learned societies but therapeutic failures are frequent and iatrogenic pathology is high Many factors have been identified as being associated with the development of chronic pain in cancer patients The intensity of preoperative pain opioid consumption age sleep disorders cognitive-emotional state psychological vulnerability and social precariousness are all factors that influence and perpetuate chronic pain linked to cancer and its management Several studies have shown that 6 months or 1 year after cancer diagnosis there are various pain trajectories enabling us to identify several pain patient phenotypes The patients overall state of vulnerability at the time of cancer diagnosis has an impact on the trajectory of pain chronicisation and it is often difficult for clinicians to apprehend this risk In practice we lack a validated easy-to-use tool that would enable us to predict the risk of pain chronicisation for each patient even before the start of the treatment process
Indeed neuropathic pain in cancer remains difficult to treat often arrives insidiously may persist well beyond cancer remission and frequently has a fate that is difficult to predict Current treatments for neuropathic pain are based on the recommendations of learned societies but therapeutic failures are frequent and iatrogenic pathology is high Many factors have been identified as being associated with the development of chronic pain in cancer patients The intensity of preoperative pain opioid consumption age sleep disorders cognitive-emotional state psychological vulnerability and social precariousness are all factors that influence and perpetuate chronic pain linked to cancer and its management Several studies have shown that 6 months or 1 year after cancer diagnosis there are various pain trajectories enabling us to identify several pain patient phenotypes The patients overall state of vulnerability at the time of cancer diagnosis has an impact on the trajectory of pain chronicisation and it is often difficult for clinicians to apprehend this risk In practice we lack a validated easy-to-use tool that would enable us to predict the risk of pain chronicisation for each patient even before the start of the treatment process
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None